Navigation Links
Bionovo Announces Third Quarter 2009 Highlights and Financial Results
Date:11/5/2009

period in 2008.

The Company commenced the quarter with $5.4 million in cash, cash equivalents and short-term investments. As of September 30, 2009, the Company had cash, cash equivalents and short-term investments of $2.3 million. In October 2009, the Company successfully completed a registered public offering of approximately 31 million shares of common stock together with approximately 29 million warrants, resulting in net proceeds to the Company of approximately $17.7 million. As of the close of the financing on October 7, 2009, the Company's cash and cash equivalents balance stood at $19.9 million.

Conference Call

The Company will conduct a conference call and webcast to review the financial results for the third quarter of fiscal year 2009 and the Company's plans for the remainder of the year at 4:45 p.m. ET on Thursday, November 5, 2009.

Interested parties can access the call by dialing (800) 860-2442 or (412) 858-4600, or can listen via a live Internet webcast, which can be found at http://bionovo.com/investors/events. A replay of the call will be available via webcast at http://bionovo.com/investors/events for 30 days or by playback at (877) 344-7529 or (412) 317-0088, conference code 434779, through November 9, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates with
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
2. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
3. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
4. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
5. Bionovo Announces First Quarter 2009 Highlights and Financial Results
6. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
7. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
8. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
9. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
10. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
11. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/14/2014)... Summer is the best season of the year for ... and other outdoor adventures. The promotional product experts at ... all summer long. The promo product gurus at 4AllPromos have ... imprinted products everyone must have on hand this summer. ... Sunscreen helps protect skin from harmful UV rays produced ...
(Date:7/14/2014)... Crystal Dental has recently announced that it ... been made via LAD Solutions in in order to increase ... made in order to draw in new patients that can ... Crystal Dental offers a variety of services for both routine ... Dental include cosmetic dentistry procedures such as porcelain veneers and ...
(Date:7/13/2014)... 14, 2014 FORT LEE, N.J. – Authors ... modern approach to the science of tooth implants ... This book describes recent advances and techniques in the ... that benefit people who have lost all of their natural ... the first lower subperiosteal implant in 1940. It was ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in ... multi-colored Quinceanera dresses to its product line. ... colorful outfits are guaranteed to be quality made. Now, ... off. , TopDresses100.com has a wide variety of elegant ... items are in stock and ready to ship. As ...
(Date:7/13/2014)... July 13, 2014 Manchester United and ... the 2014 Guinness International Champions Cup. The 2014 ICC ... each year because of the talent of it brings in. ... AS Roma will compete in the 2014 event spread across ... 24 with a game between Olympiacos and Milan and will ...
Breaking Medicine News(10 mins):Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3
... Established under the DOD Congressionally Directed Medical Research ... WASHINGTON, July 23 Today, Lung Cancer Alliance (LCA) announced ... is allotting approximately $1.2 million of the $20 million lung cancer ... , , (Logo: ...
... , , , ... , , SAN DIEGO, July 23 ... medical device company focused on developing products for minimally disruptive surgical treatments for the ... , NuVasive reported second quarter revenue of $88.5 million, a ...
... , , WASHINGTON, July ... elected John W. Bluford, president and CEO of Truman Medical Centers ... assume the chairmanship in 2011, becoming the top elected official of ... , , Bluford has been ...
... WASHINGTON, July 23 The Food and Drug Institute (FDLI) ... updated biographical information on recent Obama Administration appointees, including FDA Commissioner ... , The FDA Directory ... FDA personnel available, and contains listings of more than two dozen ...
... the epidemic might be slowing down among poor families ... preschoolers from low-income families in the United States are considered ... report finds that the news is not all bad: The ... children in this group. , Among 2- to 4-year-olds from ...
... , Woman spent remaining life in wheelchair, nursing facilities ... type , , KENT, Wash., July 23 ... Renton woman more than $1.8 million yesterday for a medical center,s ... routine back surgery. , , The ...
Cached Medicine News:Health News:Lung Cancer Alliance Announces First 'Request For Bids' for Department of Defense Lung Cancer Research Program 'Concept Awards' 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 3Health News:NuVasive Reports Second Quarter 2009 Financial Results 4Health News:NuVasive Reports Second Quarter 2009 Financial Results 5Health News:NuVasive Reports Second Quarter 2009 Financial Results 6Health News:NuVasive Reports Second Quarter 2009 Financial Results 7Health News:NuVasive Reports Second Quarter 2009 Financial Results 8Health News:NuVasive Reports Second Quarter 2009 Financial Results 9Health News:NuVasive Reports Second Quarter 2009 Financial Results 10Health News:NuVasive Reports Second Quarter 2009 Financial Results 11Health News:NuVasive Reports Second Quarter 2009 Financial Results 12Health News:AHA Board Elects John Bluford Chair-Elect Designate 2Health News:AHA Board Elects John Bluford Chair-Elect Designate 3Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 3
... The table-mounted knee ... exposure for total knee ... flexible, open-frame design allows ... the knee during the ...
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... an assayed quality control material used for ... hemoglobin fractions on CO-Oximeter instrumentation. It provides ... that parallels the human physiologic range for ... available in three (3) levels for monitoring ...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
Medicine Products: